The Zacks Analyst Blog Highlights: Isis Pharmaceuticals, Inc., Sanofi, GlaxoSmithKline, OncoGenex and Teva Pharmaceuticals

Zacks

For Immediate Release

Chicago, IL – January 14, 2013 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Isis Pharmaceuticals (ISIS), Sanofi (SNY), GlaxoSmithKline(GSK), OncoGenex (OGXI) and Teva Pharmaceuticals (TEVA).

Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks are offered free.

Here are highlights from Monday’s Analyst Blog:

Isis Pharma Updates on Pipeline

Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The company believes 5 of its pipeline candidates can get approval within the next five years. Isis Pharma expects data (phase II or phase III) on nine of its pipeline candidates in 2013.

Isis Pharma’s lead pipeline candidate, Kynamro (mipomersen), is a second generation compound being developed in collaboration with Sanofi (SNY) for the treatment of familial hypercholesterolemia (:FH). Isis Pharma received a major boost in October 2012 when the Food and Drug Administration’s (:FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted (9 - 6) in favor of approving the company’s lead pipeline candidate, Kynamro. A response from the FDA should be out by Jan 29, 2013.

However, we note that in Dec 2012, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (:EMA) rendered a negative opinion on the approval of Kynamro.

Another interesting candidate at Isis Pharma is ISIS-TTRRx. The candidate is being co-developed with GlaxoSmithKline (GSK) for the treatment of transthyretin (:TTR) amyloidosis. The companies plan to initiate a registration-directed phase II/III study evaluating the efficacy of ISIS-TTRRx on neurological dysfunction and quality-of-life in patients with familial amyloid polyneuropathy (:FAP), a type of TTR amyloidosis, shortly. The candidate received fast track designation from the FDA.

Other promising candidates in Isis Pharma’s pipeline include oncology drug, OGX-011 and EXC 001 for unwanted scarring. For OGX-011, the company has partnered with OncoGenex (OGXI) and Teva Pharmaceuticals (TEVA). Data from a phase III trial evaluating OGX-011 in prostate cancer is expected to be released at the end of 2013.

Isis Pharma carries a Zacks Rank #3 (Hold) in the short run. Though impressed by Isis Pharma’s pipeline, we expect investor focus to remain on the FDA’s decision on Kynamro.
 

Today, Zacks is promoting its ''Buy'' stock recommendations. Four daily picks are offered free.

 

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
 

 

Read the analyst report on ISIS

Read the analyst report on SNY

Read the analyst report on GSK

Read the analyst report on OGXI

Read the analyst report on TEVA

Zacks Investment Research



More From Zacks.com

Rates

View Comments (0)